Inhibikase Therapeutics Valuation
| IKT Stock | USD 2.92 0.19 6.96% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Inhibikase Therapeutics retains a regular Real Value of $8.83 per share. The prevalent price of the firm is $2.92. Our model calculates the value of Inhibikase Therapeutics from evaluating the firm fundamentals such as Return On Asset of -0.76, shares outstanding of 67.19 M, and Return On Equity of -1.5 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Inhibikase Therapeutics' valuation include:
Price Book 26.456 | Enterprise Value 180.3 M | Enterprise Value Ebitda 0.3409 | Price Sales 2.3 K | Enterprise Value Revenue 2.748 |
Undervalued
Today
Please note that Inhibikase Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Inhibikase Therapeutics is based on 3 months time horizon. Increasing Inhibikase Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Inhibikase Therapeutics' intrinsic value may or may not be the same as its current market price of 2.92, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.92 | Real 8.83 | Target 27.0 | Hype 2.93 | Naive 3.38 |
The intrinsic value of Inhibikase Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inhibikase Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Inhibikase Therapeutics helps investors to forecast how Inhibikase stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inhibikase Therapeutics more accurately as focusing exclusively on Inhibikase Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inhibikase Therapeutics' intrinsic value based on its ongoing forecasts of Inhibikase Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inhibikase Therapeutics' closest peers.
Inhibikase Therapeutics Cash |
|
Inhibikase Valuation Trend
Inhibikase Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Inhibikase Therapeutics' financial worth over time. Using both Inhibikase Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Inhibikase Therapeutics Total Value Analysis
Inhibikase Therapeutics is currently forecasted to have company total value of 180.34 M with market capitalization of 183.44 M, debt of 622 K, and cash on hands of 32.21 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Inhibikase Therapeutics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
180.34 M | 183.44 M | 622 K | 32.21 M |
Inhibikase Therapeutics Investor Information
The company recorded a loss per share of 3.12. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023. Based on the key indicators related to Inhibikase Therapeutics' liquidity, profitability, solvency, and operating efficiency, Inhibikase Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Inhibikase Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inhibikase Therapeutics has an asset utilization ratio of 1.8 percent. This implies that the Company is making $0.018 for each dollar of assets. An increasing asset utilization means that Inhibikase Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Inhibikase Therapeutics Ownership Allocation
Inhibikase Therapeutics has a total of 67.19 Million outstanding shares. Inhibikase Therapeutics retains 10.46 (percent) of its outstanding shares held by insiders and 11.62 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Inhibikase Therapeutics Profitability Analysis
The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (8.26 M).About Inhibikase Therapeutics Valuation
The stock valuation mechanism determines Inhibikase Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Inhibikase Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inhibikase Therapeutics. We calculate exposure to Inhibikase Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Inhibikase Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -13.4 M | -12.7 M | |
| Pretax Profit Margin | (73.05) | (69.40) | |
| Operating Profit Margin | (77.12) | (73.26) | |
| Net Loss | (73.05) | (69.40) | |
| Gross Profit Margin | (51.28) | (48.71) |
Inhibikase Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Inhibikase Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 5.3 M |
Inhibikase Therapeutics Current Valuation Indicators
Inhibikase Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Inhibikase Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inhibikase Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inhibikase Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inhibikase Therapeutics' worth.Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.